F M Investments LLC Takes Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)

F M Investments LLC bought a new stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 48,806 shares of the company's stock, valued at approximately $1,136,000. F M Investments LLC owned about 0.09% of Spyre Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Huntington National Bank acquired a new position in shares of Spyre Therapeutics in the fourth quarter valued at approximately $34,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in Spyre Therapeutics in the 4th quarter valued at $46,000. KLP Kapitalforvaltning AS purchased a new position in Spyre Therapeutics during the 4th quarter worth $182,000. Arizona State Retirement System boosted its holdings in shares of Spyre Therapeutics by 38.4% in the fourth quarter. Arizona State Retirement System now owns 10,115 shares of the company's stock valued at $235,000 after acquiring an additional 2,805 shares in the last quarter. Finally, Teacher Retirement System of Texas purchased a new position in Spyre Therapeutics during the fourth quarter worth about $242,000. Hedge funds and other institutional investors own 80.39% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on SYRE shares. Wolfe Research assumed coverage on Spyre Therapeutics in a research note on Tuesday, March 18th. They set an "outperform" rating and a $27.00 target price for the company. Leerink Partners initiated coverage on shares of Spyre Therapeutics in a report on Tuesday, April 8th. They issued an "outperform" rating and a $45.00 target price for the company. The Goldman Sachs Group upgraded Spyre Therapeutics to a "strong-buy" rating in a report on Tuesday, February 18th. Leerink Partnrs upgraded shares of Spyre Therapeutics to a "strong-buy" rating in a report on Tuesday, April 8th. Finally, Wedbush reaffirmed an "outperform" rating and issued a $65.00 price target on shares of Spyre Therapeutics in a report on Monday, January 13th. Eight equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $49.57.

Spyre Therapeutics Price Performance

Spyre Therapeutics stock remained flat at $12.42 during trading on Thursday. The company had a trading volume of 189,557 shares, compared to its average volume of 587,986. The stock has a fifty day moving average price of $17.83 and a two-hundred day moving average price of $23.99. Spyre Therapeutics, Inc. has a 52-week low of $10.91 and a 52-week high of $40.49. The stock has a market capitalization of $748.39 million, a PE ratio of -1.67 and a beta of 3.05.

Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.81) earnings per share for the quarter, beating analysts' consensus estimates of ($0.89) by $0.08. Equities research analysts forecast that Spyre Therapeutics, Inc. will post -4.46 EPS for the current fiscal year.

Spyre Therapeutics Profile

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).